European equities traded in the US as American depositary receipts were trending sharply higher late Wednesday morning, rising 1.72% to 1,443.47 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Grifols (GRFS) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which rose 5.2% and 4.6% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and financial services company ING Groep (ING), which were up 4.3% and 4.1% respectively.
The decliners from continental Europe were led by accommodations booking site trivago (TRVG) and furniture maker Natuzzi (NTZ), which dropped 5.4% and 2.8% respectively. They were followed by petroleum refiner Equinor (EQNR) and biotech firm Evaxion Biotech (EVAX), which were down 1.2% and 0.5% respectively.
From the UK and Ireland, the gainers were led by biotech company Autolus Therapeutics (AUTL) and alcoholic beverage company Diageo (DEO), which climbed 8.6% and 4.9% respectively. They were followed by insurance provider Prudential (PUK) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which increased 4.6% each.
The decliners from the UK and Ireland were led by biopharmaceutical company TC Biopharm (TCBP) and utilities company National Grid (NGG), which fell 8.2% and 2.5% respectively. They were followed by educational publisher Pearson (PSO) and hospitality company InterContinental Hotels (IHG), which lost 1.8% and 0.6% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.